[ad_1]
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in Regeneron Pharmaceuticals were worth $256,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Finally, American National Bank & Trust purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth $44,000. 83.31% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on REGN shares. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $754.00 to $761.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Citigroup restated a “buy” rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price objective for the company. Finally, Guggenheim increased their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research note on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $841.30.
Get Our Latest Stock Report on REGN
Regeneron Pharmaceuticals Stock Down 2.6%
Shares of NASDAQ:REGN opened at $555.13 on Thursday. The firm has a market capitalization of $59.93 billion, a P/E ratio of 13.99, a P/E/G ratio of 2.08 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.73 and a current ratio of 4.60. The stock has a 50 day moving average price of $536.31 and a 200-day moving average price of $601.45. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.56 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link